Surgical resection is the first-line treatment for human GIST, but treatment with imatinib mesylate, a tyrosine kinase inhibitor (TKI), is applicable for unresectable, metastatic, or recurrent GISTs with c-kit gene mutations [9]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.